New treatments for HIV not only must gain regulatory approval, but also must fit into the cocktail regimens that are the currently accepted mode of therapy. Trimeris Inc., which reported positive Phase II data last week for its T-20 fusion inhibitor, believes that the agent's novel mechanism of action will allow T-20 to combat cocktail-resistant HIV strains and consequently be integrated into such treatments.

T-20 is